Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CM512 in Moderate-to-Severe COPD
NCT06980142Phase 2Not yet recruiting
- Sponsor
- Keymed Biosciences
- Start
- Jun 2025
- Primary completion
- Mar 2028
- Modality
- Bispecific Antibodies
01
Overview
Phase 2, randomised, double-blind trial of CM512 in chronic obstructive pulmonary disease (COPD) (3 arms), sponsored by Keymed Biosciences. Primary endpoint: Annualised rate of moderate or severe COPD exacerbations at 52 weeks. Planned start Jun 2025; status: not yet recruiting.
02
Drugs
CM512
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT06980142.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06980142.